You are here:

aprepitant (Emend)

Advice

following a full submission:

aprepitant (Emend) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

The antiemetic regimen incorporating aprepitant was superior to one regimen (where dexamethasone alone was used in the delayed phase of treatment), for the prevention of cisplatin-induced nausea and vomiting in the acute and delayed phases. It should be initiated only by appropriate hospital based specialists.

Drug Details

Drug Name: aprepitant (Emend)
SMC Drug ID: 132/04
Manufacturer: MSD
Indication: Prevention of acute and delayed nausea and vomiting associated with chemotherapy
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 November 2004

Extra Notes

The marketing authorisation for aprepitant was extended to cover prevention of nausea and vomiting associated with highly emetogenic non-cisplatin based chemotherapy in January 2016.  This minor licence change will not be assessed.

Back